Securities code: China Meheco Group Co.Ltd(600056) securities abbreviation: China Meheco Group Co.Ltd(600056) Announcement No.: Lin 2022005 China Meheco Group Co.Ltd(600056)
Risk warning announcement
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
China Meheco Group Co.Ltd(600056) (hereinafter referred to as “the company” or “the company”) shares have deviated from the daily closing price by more than 20% in three consecutive trading days on March 1, 2022, March 2 and March 3, 2022. According to the relevant provisions of the trading rules of Shanghai Stock Exchange, it belongs to abnormal fluctuation of stock trading. The company has issued Lin 2022004 announcement on abnormal fluctuations in stock trading on March 4, 2022. On March 4, 2022, the company’s shares rose again. In view of the large fluctuation of the company’s share price recently, the relevant risks are as follows. Please pay attention to the trading risks in the secondary market, make rational decisions and invest prudently:
1、 There is no significant change in the company’s main business
The company’s main business segments include pharmaceutical industry, pharmaceutical commerce and international trade. At present, the production and operation activities are normal without significant changes.
2、 Operating performance fluctuation risk
On January 29, 2022, the company issued the announcement on the pre reduction of performance in 2021. It is estimated that the net profit attributable to the shareholders of the listed company in 2021 will be 300 million yuan to 700 million yuan, a year-on-year decrease of 77% to 47% compared with the same period of the previous year. The net profit attributable to shareholders of listed companies after deducting non recurring profits and losses was 250 million yuan to 650 million yuan, a year-on-year decrease of 79% to 45% compared with the same period of last year. The specific and accurate financial data shall be subject to the audited annual report of 2021 officially disclosed by the company.
3、 Risk tips on relevant rumors
The company is concerned about the recent rumors about the cooperation between the company and a multinational pharmaceutical company covid-19 virus treatment drugs. After verification by the company, relevant matters are under communication and negotiation, but there are still uncertainties about the specific terms of the agreement and whether it can be signed smoothly. In addition, even if the cooperation is carried out smoothly, the final use and sales of relevant drugs are also affected by factors such as epidemic prevention and control, there is great uncertainty, and it is expected that the relevant business scale accounts for a small proportion of the company’s overall business volume, which has no significant impact on the company’s recent operating performance.
The media of the information disclosure website designated by the company is the website of Shanghai Stock Exchange (www.sse. Com. CN.) And Shanghai Securities News, China Securities News, securities times and Securities Daily. Relevant information shall be subject to the announcements published by the company on the above designated websites and media.
The company’s recent stock price fluctuates greatly, and the increase may have exceeded the impact of relevant matters on the company’s performance. Please invest prudently and pay attention to investment risks.
It is hereby announced.
China Meheco Group Co.Ltd(600056) board of directors March 5, 2022
